R&D revolution could secure good, affordable prices
This article was originally published in Scrip
Companies that want to offer payers a more attractive price to secure market access for their new innovations should try a whole new approach to R&D. Step away from the randomized control trial, consult with patients and exploit data already out there, says Stuart Dollow, chief executive and founder of Vermilion Life Sciences, and you could potentially afford more flexibility on price.
You may also be interested in...
International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.
More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.